Wegovy Tablets Vs Injections

If you have been searching for an effective, medically backed solution to long-term weight management, you have probably come across the term Wegovy tablets more than once. Wegovy is one of the most talked-about weight loss treatments in the UK right now, and for good reason. It belongs to a class of medications called GLP-1 receptor agonists, which work by mimicking a natural gut hormone to reduce appetite, slow gastric emptying, and help you feel full for longer. But with so much noise online, it can be genuinely hard to separate fact from marketing. This guide is here to cut through that confusion, explain what Wegovy actually is, how it works, who qualifies for it, and what realistic results you can expect, all in plain, honest language.

Quick Summary

Wegovy (semaglutide 2.4mg) is a prescription-only weight management treatment available in the UK that has demonstrated clinically significant results in large-scale trials. It works through appetite regulation, not willpower, making it a genuine medical solution for adults struggling with obesity or weight-related health conditions.

• Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces hunger and calorie intake
• It is administered as a weekly injection, not an oral tablet, despite common search terminology
• Clinical trials show average weight loss of up to 15% body weight over 68 weeks
• Eligibility in the UK requires a BMI of 30 or above, or 27 with a weight-related condition
• It must be used alongside a reduced-calorie diet and increased physical activity for best results

Table of Contents

• What Are Wegovy Tablets and How Do They Work?
• Who Is Eligible for Wegovy in the UK?
• The Wegovy Dose Escalation Schedule Explained
• Common Side Effects and How to Manage Them
• Wegovy vs Other Weight Loss Treatments in the UK
• What Realistic Results Can You Expect?
• Key Takeaways
• When to Seek Professional Advice
• Scientific References
• Frequently Asked Questions

What Are Wegovy Tablets and How Do They Work?

Before diving into the clinical detail, it is worth addressing a very common point of confusion. Many people search for "Wegovy tablets" because they assume this is an oral medication, similar to traditional diet pills. In reality, Wegovy is a subcutaneous injection — a small, pre-filled pen that you inject just beneath the skin of your abdomen, thigh, or upper arm, once each week. The term "Wegovy tablets" has simply become a widely used search phrase, and understanding what it actually is will help you make a far more informed decision.

The active ingredient in Wegovy is semaglutide, a synthetic version of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). This hormone is released from your gut after you eat and sends signals to your brain that you are full. In people living with obesity, this signalling system is often less responsive, which makes appetite control much harder. Semaglutide mimics GLP-1 at a much higher potency than the natural hormone, binding to GLP-1 receptors in the brain's hypothalamus to meaningfully reduce hunger, food cravings, and the reward response associated with high-calorie foods.

The mechanism also involves slowing gastric emptying, which means food leaves your stomach more slowly. This contributes to that feeling of sustained fullness that many patients describe after meals. Critically, this is not simply suppressing hunger artificially — it is working with a biological pathway your body already uses. That distinction matters when considering long-term safety and sustainability. Unlike older weight loss medications that acted on the central nervous system through stimulant pathways, Wegovy works peripherally and centrally through a well-understood hormonal route.

• Semaglutide is the active ingredient, originally developed to treat type 2 diabetes
• The 2.4mg weekly dose used in Wegovy is higher than that used in diabetes treatment (Ozempic)
• It works on appetite, reward signalling, and gastric motility simultaneously
• It is injected, not swallowed — the term "Wegovy tablets" refers to the product, not the form

Who Is Eligible for Wegovy Tablets in the UK?

One of the most common pain points people face when exploring weight loss medication is simply not knowing whether they qualify. Eligibility for Wegovy in the UK is defined by clinical criteria set out by both the Medicines and Healthcare products Regulatory Agency (MHRA) and, for NHS use, the National Institute for Health and Care Excellence (NICE). Understanding these criteria upfront will save you considerable time and frustration.

To be eligible for Wegovy, you generally need a body mass index (BMI) of 30 kg/m² or above. Alternatively, if your BMI is 27 or above but you have at least one weight-related health condition — such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease — you may also qualify. The treatment is intended for adults aged 18 and over, and it is not recommended during pregnancy or breastfeeding. There are also certain contraindications, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

In 2026, NICE guidance continues to support the use of semaglutide for weight management within specialist weight management services, but private prescribing through regulated online pharmacies and clinics has also expanded access significantly for those who do not qualify for NHS provision. If you are exploring this route, always ensure your prescriber is registered with the General Pharmaceutical Council (GPhC) or the General Medical Council (GMC) and that a proper medical consultation is conducted before any prescription is issued.

• BMI of 30 or above for standard eligibility
• BMI of 27 or above if you have a weight-related comorbidity
• Must be an adult aged 18 or over with no contraindicated conditions
• Not suitable during pregnancy, breastfeeding, or with a history of certain thyroid cancers
• Private prescribing is legal and widely available through regulated UK services

The Wegovy Dose Escalation Schedule Explained

One of the most important things to understand about Wegovy is that you do not start at the full therapeutic dose. There is a carefully structured escalation schedule that gradually increases your weekly dose over approximately 16 to 17 weeks. This approach is intentional and clinically designed to allow your body to adapt, significantly reducing the likelihood of gastrointestinal side effects that many people worry about when they first read the patient information leaflet.

The escalation begins at 0.25mg once weekly for the first four weeks. This is a sub-therapeutic dose, meaning it is not yet at the level required for weight loss — it simply acclimatises your digestive system to the medication. After four weeks, the dose increases to 0.5mg weekly, then to 1.0mg, then 1.7mg, before reaching the maintenance dose of 2.4mg once weekly from week 17 onwards. If you find a particular step difficult to tolerate due to nausea or digestive discomfort, your prescriber may recommend staying at a lower dose for a longer period before advancing.

It is worth knowing that for some patients, staying at the 1.7mg dose is appropriate if 2.4mg causes persistent side effects that significantly affect quality of life. Your prescriber will help guide that decision based on your individual experience. Never skip dose steps or increase your dose faster than instructed — doing so dramatically increases the risk of adverse effects and does not meaningfully accelerate weight loss.

Week	Dose	Purpose	What to Expect
Weeks 1–4	0.25mg once weekly	Tolerability induction	Minimal appetite change; body adjusting
Weeks 5–8	0.5mg once weekly	Initial therapeutic effect	Early appetite reduction may begin
Weeks 9–12	1.0mg once weekly	Increased efficacy	Noticeable fullness after smaller meals
Weeks 13–16	1.7mg once weekly	Near-maintenance dose	Significant appetite suppression
Week 17 onwards	2.4mg once weekly	Maintenance dose	Full therapeutic effect; maximum weight loss potential

Common Side Effects and How to Manage Them

Side effects are one of the most searched topics when people investigate Wegovy, and it is easy to understand why. Reading a long list of potential adverse reactions can feel alarming, particularly if you are already anxious about trying a new medication. The reality, however, is that the vast majority of side effects associated with Wegovy are mild to moderate, tend to occur early in treatment, and typically improve as your body adjusts to each dose step.

The most commonly reported side effects are gastrointestinal in nature. These include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. Nausea is particularly common in the early weeks and is largely the result of gastric emptying slowing down. Most patients find that eating smaller meals, avoiding high-fat or heavily spiced foods, and not lying down immediately after eating makes a significant difference. Staying well hydrated is also important, particularly if you experience any vomiting or loose stools.

More serious but rare side effects include pancreatitis, gallbladder problems, and changes in heart rate. If you experience severe and persistent abdominal pain that radiates to your back, you should stop the medication and seek urgent medical attention, as this could indicate pancreatitis. It is also worth noting that Wegovy may affect how your body absorbs oral medications, including the oral contraceptive pill, due to its effects on gastric emptying. Discuss this with your prescriber when reviewing your full medication list. For those managing digestive discomfort alongside Wegovy, exploring heartburn and indigestion relief options may provide useful additional support during the early weeks.

• Nausea is the most common side effect and usually improves after the first few weeks
• Eating smaller, lower-fat meals can significantly reduce gastrointestinal discomfort
• Serious side effects such as pancreatitis are rare but require immediate medical attention
• Report any persistent or worsening symptoms to your prescriber promptly
• The oral contraceptive pill may be less effective during Wegovy treatment — use additional contraception

Wegovy vs Other Weight Loss Treatments in the UK

With several weight loss treatments now available in the UK, it is understandable to feel uncertain about which option is right for you. The landscape has changed considerably in recent years, with newer medications entering the market alongside established options. Understanding how Wegovy compares to these alternatives can help you have a more productive conversation with your prescriber and make a genuinely informed choice.

The most frequently compared treatment is Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist that has shown slightly higher average weight loss in clinical trials — up to 22.5% body weight loss compared to Wegovy's 14.9%. However, individual response varies significantly, and Mounjaro's dual mechanism may carry different side effect profiles for some patients. Another commonly discussed option is Orlistat (available as Orlos), which works entirely differently by blocking the absorption of dietary fat in the gut. Orlistat is available without a prescription at lower doses, making it more accessible but also generally less potent than injectable GLP-1 medications.

Over-the-counter supplements such as XLS Medical Weight Loss Plus and XLS Medical Direct Fat Binder represent a non-prescription tier of support. These can be useful adjuncts for people at the lower end of the weight concern spectrum, but they are not equivalent to prescription GLP-1 therapies in terms of evidence or effect size. The key question is not which treatment is objectively best, but which is most appropriate for your BMI, health profile, lifestyle, and medical history.

• Mounjaro (tirzepatide) may produce slightly greater average weight loss but works through a dual mechanism
• Orlistat is a lower-cost, partially OTC option that blocks fat absorption rather than reducing appetite
• OTC supplements like XLS Medical offer accessible but less potent support for mild weight management
• Wegovy is uniquely suited to those for whom appetite and satiety regulation is the primary barrier

What Realistic Results Can You Expect From Wegovy Tablets?

Let us be honest about something that often gets lost in the excitement around Wegovy: it is not a miracle. It is a highly effective medical tool, but it works best when used as part of a broader lifestyle programme that includes a reduced-calorie diet and regular physical activity. The clinical trial data is genuinely impressive, but it was collected in controlled environments where participants also made behavioural changes. Understanding this sets you up for sustainable, long-term success rather than disappointment.

The landmark STEP 1 trial, which assessed Wegovy tablets (semaglutide 2.4mg) over 68 weeks, found that participants lost an average of 14.9% of their body weight compared to just 2.4% in the placebo group. To put that in real terms, a person starting at 100kg could expect to lose approximately 14–15kg over the course of the full treatment period. Roughly one in three participants in the trial lost more than 20% of their body weight. These are results that far exceed anything previously seen with lifestyle intervention or older weight loss medications, which is why Wegovy has rightly attracted significant clinical attention.

It is also important to understand what happens when you stop. Weight regain is a known concern with GLP-1 medications. Clinical data shows that patients regain a significant portion of lost weight within one to two years of discontinuing treatment, which underscores the fact that obesity is a chronic condition requiring ongoing management. For many people, long-term or indefinite treatment may be appropriate, particularly where weight-related comorbidities are present. Your prescriber will review your progress regularly and help you decide on the most appropriate long-term plan. Maintaining muscle mass during weight loss is also important, and a good prescriber will discuss the role of resistance exercise alongside your Wegovy treatment.

• Average weight loss of 14.9% body weight over 68 weeks in the STEP 1 trial
• Approximately one in three patients lost more than 20% of their starting body weight
• Results are significantly better when combined with dietary changes and physical activity
• Weight regain is likely after stopping — discuss long-term treatment plans with your prescriber
• Regular monitoring, typically every 12 weeks, helps track progress and adjust the approach

Key Takeaways

• Wegovy is a weekly injectable semaglutide treatment for weight loss — not an oral tablet despite common search phrasing
• It works by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve satiety signalling
• Eligibility requires a BMI of 30 or above (or 27 with a weight-related condition) and a proper medical consultation
• A gradual dose escalation over 16 weeks minimises side effects and improves long-term tolerability
• Clinical trials demonstrate up to 14.9% average body weight loss at the full 2.4mg maintenance dose

When to Seek Professional Advice

While Wegovy is a safe and well-studied medication when prescribed appropriately, there are specific situations where you should seek medical advice promptly rather than waiting for your next scheduled review. Knowing these red flags helps you stay safe throughout treatment.

Contact your prescriber or a healthcare professional immediately if you experience severe abdominal pain that does not pass, especially if it radiates to your back, as this may indicate pancreatitis. Similarly, any signs of an allergic reaction — including swelling of the face, lips, throat, or tongue, difficulty breathing, or severe skin reactions — require urgent attention. If you develop yellowing of the skin or eyes, significant changes in your urine colour, or persistent upper abdominal pain, these may indicate gallbladder problems and warrant prompt assessment.

You should also speak to your prescriber before starting Wegovy if you take medications for blood pressure, cholesterol, or diabetes, as your dosing requirements for those medications may change as you lose weight. If you experience a sustained and unexplained rapid heart rate while on treatment, flag this at your earliest opportunity. Finally, if you are not seeing any weight loss after 16 weeks at the full maintenance dose and have been following the recommended lifestyle programme consistently, a clinical review is warranted to consider whether the treatment is right for you or whether an alternative approach may be more effective.

Frequently Asked Questions

How long does it take for Wegovy tablets to start working?

Wegovy tablets typically begin to show noticeable appetite reduction within the first one to two weeks of starting treatment. Meaningful weight loss, however, is usually observed from around four to eight weeks onwards, with the most significant results seen after 12 to 16 weeks as the dose is gradually increased to the maintenance level.

Is Wegovy safe for long-term use in the UK?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified UK healthcare professional. Clinical trials including the STEP programme have demonstrated sustained safety over 68 weeks, and as of 2026, NICE guidelines support its use within approved NHS and private prescribing pathways for eligible adults.

Can you take Wegovy tablets with other medications?

Wegovy tablets can interact with certain medications, particularly those used to manage diabetes or blood pressure, as weight loss may alter how these drugs work. You should always inform your prescriber of every medication you take, including over-the-counter products and supplements, before starting Wegovy to ensure it is safe for you.

What is the correct dose of Wegovy tablets?

The correct dose of Wegovy follows a gradual escalation schedule starting at 0.25mg once weekly for the first four weeks, increasing in stages to the maintenance dose of 2.4mg once weekly by week 17. This slow titration is specifically designed to minimise gastrointestinal side effects and improve long-term tolerability for patients.

Scientific References

1. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity (TA875). NICE, 2023.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The Lancet, 2021; 384(10):989–1002.
3. Medicines and Healthcare products Regulatory Agency (MHRA). Wegovy (semaglutide) Summary of Product Characteristics. MHRA, 2023.